How do I switch a patient from immediate-release lamotrigine 150 mg in the morning and 75 mg at night to extended-release lamotrigine at the same total daily dose, and should the XR formulation be taken once daily or twice daily for full effectiveness?

Switching from Immediate-Release to Extended-Release Lamotrigine

Convert your patient to lamotrigine extended-release (XR) 225 mg once daily, taken at the same time each morning, using a 1:1 total daily dose conversion from her current 225 mg/day immediate-release regimen.

Dosing Schedule: Once Daily Only

The extended-release formulation is specifically designed for once-daily administration 1. Taking it twice daily would negate the pharmacokinetic advantages of the XR formulation and is not the intended use.

Conversion Protocol

Direct 1:1 Conversion

• Current regimen: IR 150 mg AM + 75 mg PM = 225 mg total daily
• New regimen: XR 225 mg once daily (morning preferred)
• Timing: Make the switch abruptly; no titration needed when converting between formulations at equivalent doses 1

Pharmacokinetic Rationale

The COMPASS study demonstrated that steady-state trough concentrations remain similar when converting from twice-daily IR to once-daily XR at the same total daily dose 1. Key findings:

• Trough levels maintained: Dose-normalized trough concentrations of XR were equivalent to IR formulations
• Reduced peak fluctuation: XR provides more stable serum levels throughout the day, with lower peak concentrations (Cmax) but similar overall drug exposure (AUC)
• Extended absorption: Time to peak concentration (Tmax) with XR ranges from 4-11 hours depending on concomitant medications, versus 1-1.5 hours for IR 1

Clinical Advantages of Conversion

Real-world data shows meaningful benefits beyond convenience 2:

• Improved seizure control: 47% of patients experienced >50% reduction in seizure frequency after conversion
• Better tolerability: Reduced peak-related adverse effects (dizziness, diplopia, ataxia) due to lower Cmax
• Higher trough levels: May improve seizure threshold compared to IR formulations

Important Caveats

Concomitant Medications Matter

If your patient is taking enzyme-inducing antiepileptics (carbamazepine, phenytoin, phenobarbital), be aware that one study showed XR had 21% lower AUC compared to IR in this population 1. Monitor clinically and consider checking a lamotrigine level 2-4 weeks post-conversion if seizure control worsens.

Monitoring Strategy

• Baseline level: Consider checking a lamotrigine level on current IR regimen before switching
• Post-conversion level: Recheck 2-4 weeks after conversion to confirm therapeutic range maintained
• Clinical monitoring: Assess for both breakthrough seizures (suggesting lower levels) and adverse effects

Formulation Availability

Extended-release lamotrigine is available in 25,50,100,200,250, and 300 mg tablets 3. For your patient's 225 mg dose, she would take one 200 mg + one 25 mg tablet together once daily.

Practical Implementation

1. Discontinue IR: Stop the 150 mg AM and 75 mg PM doses
2. Start XR: Begin 225 mg XR the next morning (200 mg + 25 mg tablets)
3. Timing: Advise consistent daily timing, preferably morning to minimize any potential sleep interference
4. Swallowing: XR tablets must be swallowed whole; cannot be crushed or chewed

The once-daily dosing may also improve adherence, as simulations show XR formulations are more forgiving of minor dosing delays compared to twice-daily IR regimens 4.